Compare Supplements

Approved (postmenopausal women) / off-label (male) — clinician-directed. For osteoporosis treatment/prevention and breast-cancer risk reduction the standard, validated dose is 60 mg once daily (the MORE, CORE, RUTH and STAR trials all used 60 mg/day; MORE also tested 120 mg/day with no clear added fracture benefit and more side effects). For off-label male gynecomastia the small published pediatric series used roughly 60 mg/day; there is no FDA-approved male dose and the male evidence is thin and retrospective.

Any time

Raloxifene hydrochloride 60 mg tablets (approved for postmenopausal osteoporosis and breast-cancer risk reduction)

Approved (oncology) / off-label (male) — clinician-directed. For ER-positive breast cancer the standard adjuvant dose is 20 mg once daily for 5-10 years. For off-label male gynecomastia, the randomized trials used roughly 10-20 mg daily (10 mg/day prophylactically alongside an antiandrogen, 20 mg/day to treat established gynecomastia). For idiopathic male infertility, the trials typically used 20 mg/day. Bodybuilding 'post-cycle therapy' commonly uses 10-40 mg/day tapered — a use with no controlled-trial evidence. There is no FDA-approved male dose.

Any time

Tamoxifen citrate tablets (approved for breast cancer; off-label in men)

• Active or past history of venous thromboembolism (deep-vein thrombosis, pulmonary embolism, retinal-vein thrombosis) — raloxifene raises clot risk
• Pregnancy and breastfeeding (can harm the fetus; contraindicated)
• Women of childbearing potential / premenopausal women (not indicated)

• Warfarin / anticoagulants
• Cholestyramine
• Systemic estrogens / other SERMs / aromatase inhibitors

• History of venous thromboembolism (deep-vein thrombosis or pulmonary embolism) or stroke — tamoxifen raises clot risk
• Concurrent warfarin / anticoagulant therapy in the prevention setting (per label)
• Pregnancy and breastfeeding (can harm the fetus)

• Warfarin / anticoagulants
• Strong CYP2D6 inhibitors (e.g. paroxetine, fluoxetine, bupropion)
• Aromatase inhibitors / other SERMs / exogenous estrogens